To the best of our knowledge, the present study is the first to report the serum levels of TGF-β1 determined before radiotherapy and after the 25th radiotherapy fraction in prostate cancer patients to be significantly positively associated with acute GU radiotoxicity symptoms. This evidence concerns the gene TGFB1 and prostate carcinoma.